■ The efficacy of PDE5 inhibitors in diabetic patients
Agnieszka Swiecicka
Andrology. 2023 Feb; 11(2): 245–256
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107754/
■ Phosdiesterase 5 (PDE-5 inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review
A Shafiee, R A Bahri, M M Teymouri et al
BMC Gastroenterol 2023, vol 23: 170
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201782/
■ Exploring the multifaceted potential of sildenafil in Medicine
Ciprian Pușcașu, Anca Zanfirescu, Simona Negreș, Oana Cristina Șeremet
Medicina (Kaunas) 2023 Dec; 59(12): 2190
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10744870/
■ Sildenafil and kidney function in heart failure with preserved ejection fraction
Daniel Edmonston, Matthew Sparks, Sudarshan Rajagopal, Myles Wolf
Kidney360. 2023 May; 4(5): 631–640
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278830/
■ Advancement in phosphodiesterase 5 inhibitors: unveiling presente and future perspectives
Ahmed K. ElHady, Dalia S. El-Gamil, Mohammad Abdel-Halim, Ashraf H. Abadi
Pharmaceuticals (Basel) 2023 Sep; 16(9): 1266
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536424/
■ Predictors of the response to phosphodiesterase-5 inhibitors in pulonary arterial hypertension: an analysis of the Spanish registry
Agustin R. Garcia, Isabel Blanco, Lluis Ramon, et al
Respir Res. 2023; 24: 223
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503122/
■ Unmasking hidden risks: the surprising link between PDE5 inhibitors and seizure susceptibility
Alex Luiz Menezes da Silva, Chirlene Pinheiro Nascimento, Julianne Elba Cunha Azevedo et al
PLoS One. 2023; 18(11): e0294754.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688920/
■ Treating diabetes with combination of phosphodiesterase 5 inhibitos and hydroxychloroquine – a possible prevention strategy for COVID-19?
Rakesh C. Kukreja, Rui Wang, Saisudha Koka, Anindita Das, Arun Samidurai, Lei Xi
Mol Cell Biochem. 2023; 478(3): 679–696
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421626/
■ Risk of ocular adverse events associated with use of phosphodiesterase 5 inhibitors in men in the US
Mahyar Etminan, Mohit Sodhi, Frederick S. Mikelberg, David Maberley
JAMA Ophthalmol. 2022 May; 140(5): 480–484.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990352/
■ Outcomes with phosphodiesterase-5 inhibitors use after lefet ventricular assist device: A STS-INTERMACS Analysis
- Wilson Grandin, Gaurav Gulati, Jose I Nunez, Kevin Kennedy, et al
Circ Heart Fail. 2022 Apr; 15(4): e008613
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205418/
■ Assessment of combination therapies vs monotherapy for erectile dysfunction
I Mykoniatis, N Pyrgidis, I Sokolakis et al
JAMA Netw Open 2021, vol 4 (2): e2036337
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893498/
■ Phosphodiesterase-5 inhibitors and the heart: compound cardioportection?
D C Hutching, S G Anderson, J L Caldwell, A W Trafford
Heart 2018, vol 104 (issue 15)
https://heart.bmj.com/content/104/15/1244
■ Acesso gratuito
■ Um dos Blog de Medicina mais acessado em todo o mundo. Mais de 1250 temas médicos já disponíveis online
■ Use o mecanismo de busca – PESQUISAR na home page.
■ Acesse ARQUIVO e encontre os temas incluídos no Blog a cada mês, desde maio 2017
■ Blog Internet Médica – www.internetmedica.com.br
■ Médico Responsável: Dr Paulo Fernando Leite
CRMMG: 7026
Consultório (Novo Endereço): Rua Rio Grande do Norte 23/ 9 andar
Tels 996346835 32438504
Belo Horizonte/MG/Brasil
Email: pfleite1873@gmail.com
Fevereiro 2024